breast cancer drugs


The Biomarkers Consortium, a public-private alliance that includes the US Food and Drug Administration, the National Institutes of Health and major pharmaceutical companies, announced the start of the I-SPY 2 trial at a news conference this morning at NIH headquarters in Bethesda, Md. The project is led by the Foundation for the National Institutes of Health. MD Anderson will be one of the first of 20 national clinical trial sites to open. The trial combines personalized medicine with an innovative adaptive randomization approach designed to match each womans tumor with the drug most likely to control her disease.